Clinical Trial Update: Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study [Phase 1, Phase 2]

View source ↗

Summary

A prospective Phase Ib/II trial in colorectal cancer evaluating Fruquintinib with a checkpoint inhibitor, either in combination with TAS-102 or as sequential TA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING